Join the Jobevne group to help and get support from people like you.
Jobevne News
Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
MONDAY, May 12, 2025 – The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors, according...
FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar to Avastin
BRIDGEWATER, New Jersey and BENGALURU, Karnataka, India, April 10, 2025 – Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food...
Further information
Related condition support groups
Colorectal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Renal Cell Carcinoma